No abstract

YOuNg CHilDREN's MEANiNg-MAKiNg is a multifaceted, complex experience, where thought, body and emotion unite. Rich and intricate creations are brought to life through children's formation, communication and interpretation of 'signs' which stand for or represent something else. The term drawing-telling is used to describe children's use of a range of signs when depicting imaginary worlds on paper, on the topic of what they think the future might be like. Such depictions include an expansive range of signs-narration, gesture, graphic depiction, onomatopoeia-often used in highly interactive ways. This paper illustrates, through examples of young children's drawings and transcripts of their 'tellings', the intertextual nature of their work. It foregrounds how adults must be sensitive to children's shifts between various subject positionings and the multiple functions that may be assigned to their depicted objects and events. Similarities between drawing-telling and filmic textual features are featured to assist adults in understanding children's meaning-making. introduction We seem as a species to be driven by a desire to make meanings: above all, we are surely homo significansmeaning-makers. (Chandler, 2002, p. 17) YOuNg CHilDREN ARE meaning-makers par excellence. They use many signs to create meaning and to represent reality within the medium of drawingtelling. Their artistic communication involves a combination of both verbal and non-verbal texts, such as artworks which incorporate narration, music that has lyrics, or dance which includes expressive vocalisation. So, in a broad sense, such texts are an 'assemblage of signs' (Chandler, 2002, p. 3).

Reinfusion of PBPC collected in a single leukapheresis accelerates engraftment in the majority of patients. Pretreatment bone marrow CD34+ cell content determines PBPC mobilization capacity and may help select hematopoietic rescue strategies.

Twenty-five patients with major ABO blood group incompatibility between donor and recipient underwent allogeneic bone marrow transplantation using erythrocyte depletion of the bone marrow infusate prior to administration. Over 95% of the original erythrocyte content of the marrows was removed, while retaining 75% of the mononuclear cell content and 57% of the granulocyte-monocyte colony-forming units. Recipients, well hydrated and premedicated with corticosteroids, diphenhydramine, and mannitol, tolerated infusions well. The frequency of engraftment, rate of recovery of peripheral blood leukocytes, granulocytes, and platelets, and the incidence of graft-versus-host disease was similar to that observed following ABO blood group compatible bone marrow transplantation. Erythroid development following ABO blood group incompatible transplantation was significantly impaired until hemagglutinins fell to 1:4 or lower, at which time recovery of erythrocytes was detected in the peripheral blood. The erythrocyte hypoplasia associated with incompatible hemagglutinins was temporary. Erythrocyte purging is a safe and effective technique to perform bone marrow transplantation across major ABO blood group incompatibilities.

The use of peripheral blood progenitor cells (PBPC) for hematopoietic rescue after high-dose chemotherapy is limited by the number of leukaphereses required to collect an adequate number of hematopoietic progenitors. To optimize the collection of PBPC, we evaluated a single large-volume leukapheresis protocol with citrate anticoagulation. A group of 23 patients received cyclophosphamide (4 g/m2) and GM-CSF (5 micrograms/kg/day for 15 days) as PBPC mobilization, with a single outpatient 6 h leukapheresis performed on the COBE Spectra 15 days later. Citrate (0.190 mmol/ml) was infused at 1.2 ml/L of blood/minute with a whole blood to citrate ratio between 17:1 and 25:1. Calcium chloride (50 mM) was administered at a citrate to calcium molar ratio between 10:1 and 5:1 to prevent hypocalcemia. A median 36.6 L (range 24.4-46.4) blood was processed using 338 mM citrate (269-473) and 50 mM calcium (25-75). A median 5 x 10(6) CD34+ cells/kg (< 0.3-24) and 6.2 x 10(5) CFU-GM/kg (< 0.001-29) were collected, representing 5.6 and 5.9 more PBPC, respectively, than were in circulation at the initiation of leukapheresis. We conclude that a 6 h large-volume leukapheresis following cyclophosphamide and GM-CSF mobilization is safe, can recruit hematopoietic progenitors into the circulatory compartment, and allows the collection of high numbers of PBPC in a single procedure.